What is Cancer News Daily?

Cancer News Daily is a comprehensive cancer research news aggregator that collects and curates the latest research articles from 120+ trusted medical journals and cancer research institutions worldwide. We provide free access to breakthrough treatments, clinical trials, nutrition research, and new technology in oncology.

How often is content updated?

Our automated system fetches new cancer research articles every 2 hours from 120+ authoritative medical journals across 5 continents, ensuring you always have access to the latest breakthroughs.

What sources does Cancer News Daily aggregate from?

We aggregate content from 120+ trusted sources including top-tier journals like Nature Cancer, The Lancet Oncology, JAMA Oncology, Cancer Cell, major cancer centers like MD Anderson and Memorial Sloan Kettering, government organizations like NCI and NIH, and international research institutions across North America, Europe, Asia-Pacific, and beyond.

Is Cancer News Daily free to use?

Yes, Cancer News Daily is completely free to access. We believe life-saving cancer research should be accessible to everyone - patients, caregivers, researchers, and medical professionals worldwide.

[Articles] Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study

The Lancet Oncology | December 23, 2025 | Yi-Long Wu, Yu Yao, Jin-Ji Yang, Lin Wu, Wei Zhang, Ying Wang, Hai-Peng Xu, Yong Song, Yan Zhang, Jun Zhao, Jing-Hua Chen, Zhe-Hai Wang, Qi-Ming Wang, Jie Hu, Xing-Ya Li, Yun Fan, Yuan Chen, Jian Fang, Di Han, Wei-Zhe Xue, Si-yang Maggie Liu, Qing Zhou, Pei-Long Zhang, He-Peng Shi

Vebreltinib showed antitumour activity in patients with MET amplification-driven advanced NSCLC who had previously received chemotherapy or were chemotherapy-naive. Further research is needed to validate these findings.

Topics: lung-cancer, blood-cancer, chemotherapy, clinical-trials, research

Read the full article at The Lancet Oncology